aTYR PHARMA (ATYR) Cash & Equivalents (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Cash & Equivalents data on file, last reported at $10.0 million in Q1 2026.

• Quarterly Cash & Equivalents fell 3.42% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (down 3.42% YoY) and the FY2025 annual result came in at $10.7 million, down 2.82% from the prior year.
• Cash & Equivalents declined to $10.0 million in Q1 2026, from $10.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $22.5 million in Q4 2023 to a low of $6.1 million in Q3 2025.
• A 5-year average of $11.8 million and a median of $10.4 million in 2025 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 327.27% in 2022, down 69.27% in 2022.
• Tracing ATYR's Cash & Equivalents over 5 years: stood at $10.0 million in 2022, then surged by 125.87% to $22.5 million in 2023, then plunged by 50.96% to $11.1 million in 2024, then slipped by 2.82% to $10.7 million in 2025, then dropped by 6.84% to $10.0 million in 2026.
• The last three Cash & Equivalents figures came in at $10.0 million (Q1 2026), $10.7 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.